Novartis has agreed to acquire Seattle-based biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease. The transaction, in the form of a merger of a newly-formed Novartis unit and Chinook, is…
#novartis #seattle #chinooktherapeutics #vasnarasimhan #narasimhan #astrazeneca #caucasian #sandoz
Continue reading...